acute myeloid leukemia
drug delivery
gold nanoparticles
in vivo imaging system
in vivo models
tyrosine kinases
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2024
2024
Historique:
received:
05
02
2024
accepted:
18
04
2024
medline:
27
5
2024
pubmed:
27
5
2024
entrez:
27
5
2024
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) is a malignancy in the myeloid lineage that is characterized by symptoms like fatigue, bleeding, infections, or anemia, and it can be fatal if untreated. In AML, mutations in tyrosine kinases (TKs) lead to enhanced tumor cell survival. The most frequent mutations in TKs are reported in
Identifiants
pubmed: 38799169
doi: 10.3389/fphar.2024.1382399
pii: 1382399
pmc: PMC11116693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1382399Informations de copyright
Copyright © 2024 Munteanu, Tigu, Feder, Tatar, Gulei, Tomuleasa and Boca.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.